Core Insights - The discussion will focus on the high unmet need and lack of FDA-approved treatment options for acute agitation episodes in Alzheimer's dementia, affecting approximately 100 million episodes annually [1][2]. Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience [6]. - The company is advancing preparations for the TRANQUILITY In-Care Phase 3 trial, which is a double-blind, placebo-controlled study evaluating BXCL501 for treating acute agitation episodes in Alzheimer's dementia [4][9]. Product Information - BXCL501 is a late-stage product candidate being evaluated for acute agitation episodes in Alzheimer's dementia, with no current FDA-approved therapies for this condition [3][8]. - BXCL501 has received Breakthrough Therapy designation from the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for agitation associated with schizophrenia and bipolar disorders [8]. Clinical Trial Details - The TRANQUILITY In-Care trial aims to enroll approximately 200 patients aged 55 and older with mild to severe dementia, assessing the efficacy and safety of a 60 mcg dose of BXCL501 over a 12-week period [9]. - The primary endpoint of the trial is a change from baseline in the Positive and Negative Syndrome Scale-Excitatory Component total score at two hours post-first dose [9]. Event Information - A virtual key opinion leader (KOL) roundtable will be held on February 27, 2026, to discuss acute agitation episodes in Alzheimer's dementia and the potential role of BXCL501 [1][2][4]. - The event will be moderated by Anjalee Khemlani, an award-winning healthcare journalist [4]. Expert Panel - The roundtable will feature medical professionals specializing in geriatric psychiatry and Alzheimer's care, including George T. Grossberg, MD, and Anton P. Porsteinsson, MD [7].

Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of developmentReports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Madr ...

Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were accepted for oral presentations at the 49th Macula Society Annual Meeting, taking place February 25-28 in San Diego, California. New data to be presented include the comprehensive analysis from the GALE extension study fo ...

Core Viewpoint - Syndax Pharmaceuticals will report its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call and live audio webcast to discuss the results and provide a business update [1]. Group 1: Financial Results Announcement - The earnings release is scheduled for Thursday, February 26, 2026 [1]. - A conference call and live audio webcast will take place at 4:30 p.m. ET on the same day [1]. Group 2: Access Information - The live audio webcast and accompanying slides can be accessed through the Events & Presentations page in the Investors section of the Company's website [2]. - Conference ID for the call is Syndax4Q25, with domestic dial-in number 800-590-8290 and international dial-in number 240-690-8800 [2]. - A replay of the conference call will be available approximately 24 hours after the event and will remain accessible for 90 days [2]. Group 3: Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3]. - Key products in the pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3]. - The company is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [3].

分组1 - Meridian Small Cap Growth Fund reported a 0.90% net return in Q4 2025, underperforming the Russell 2000 Growth Index which returned 1.22% [1] - The fund's annual return for small caps was 12.8%, with a quarterly gain of 2.2% [1] - The market was influenced by optimism regarding monetary easing and strong AI-related earnings, although sentiment cooled later in the quarter [1] 分组2 - Structure Therapeutics Inc. (NASDAQ:GPCR) focuses on developing oral small-molecule therapeutics for chronic diseases, with a market capitalization of $4.829 billion [2][3] - The stock of Structure Therapeutics Inc. closed at $68.36 on February 18, 2026, with a one-month return of -25.59% but a twelve-month increase of 192.26% [2] - The company's lead oral candidate has shown promising efficacy and a favorable safety profile, positioning it as a potential acquisition target in the GLP-1 competitive landscape [3]

Zinger Key Point:MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST)Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) , a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with an increasing focus on products to treat or prevent gastrointestinal cancers, has added a new phase 1-ready candidate to its portfolio, this time to target gastrointestinal stromal tumors, or GIST. MTX240's ...

Core Insights - Principal Financial Group Inc. acquired 45,205 shares of Stoke Therapeutics, valued at approximately $1,062,000, representing about 0.08% of the company [2] - Several institutional investors have increased their stakes in Stoke Therapeutics, indicating growing interest in the company [3] - Research firms have provided positive ratings and price targets for Stoke Therapeutics, suggesting a favorable outlook for the stock [4] Institutional Investment - Marshall Wace LLP increased its position by 7.9%, owning 2,300,554 shares valued at $26,111,000 after acquiring an additional 168,771 shares [3] - Goldman Sachs Group Inc. raised its stake by 21.4%, now holding 1,662,039 shares worth $11,053,000 after purchasing 293,072 shares [3] - Assenagon Asset Management S.A. boosted its position by 67.3%, owning 900,272 shares valued at $21,156,000 after acquiring 362,299 shares [3] Analyst Ratings - Guggenheim initiated coverage with a "buy" rating and a price target of $60.00 [4] - JPMorgan Chase & Co. raised its price target from $15.00 to $25.00, maintaining a "neutral" rating [4] - The consensus rating for Stoke Therapeutics is "Moderate Buy" with a target price of $39.18 [4] Stock Performance - Stoke Therapeutics shares opened at $30.98, with a 52-week low of $5.35 and a high of $38.69 [5] - The company has a market capitalization of $1.77 billion and a PE ratio of 46.24 [5] - The 50-day moving average price is $31.54, while the 200-day moving average price is $27.33 [5] Insider Activity - Director Edward M. Md Kaye sold 13,430 shares at an average price of $32.27, resulting in a 21.47% decrease in his position [6] - General Counsel Jonathan Allan sold 3,978 shares at an average price of $32.28, leading to a 25.16% decrease in his ownership [6] - Over the last 90 days, insiders sold 58,302 shares valued at $1,826,430, with insiders owning 9.50% of the company's stock [6] Company Overview - Stoke Therapeutics is a clinical-stage biopharmaceutical company focused on developing genetic medicines for rare neuromuscular and neurological disorders [8] - The company utilizes its proprietary TANGO™ platform to design antisense oligonucleotides that enhance protein expression [8] - The lead program, STK-001, targets the sodium channel protein SCN1A for the treatment of Dravet syndrome [9]

Oppenheimer & Co. Inc. acquired a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 7,845 shares of the company’s stock, valued at approximately $407,000. Get BridgeBio Pharma alerts: Several other large investors have also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp bought a new position in shares of BridgeBio Pharma in the firs ...

Core Viewpoint - BioVersys AG announced promising Phase 2a clinical trial results for AlpE, a novel antibacterial product aimed at treating pulmonary tuberculosis (TB), published in the New England Journal of Medicine, highlighting its potential to address multidrug-resistant (MDR) TB [1][7]. Company Overview - BioVersys AG is a clinical stage biopharmaceutical company focused on developing novel antibacterial products for serious infections caused by MDR bacteria, with its most advanced programs targeting nosocomial infections and tuberculosis [14]. Clinical Trial Details - The Phase 2a bEto-TB clinical trial, conducted in South Africa, demonstrated AlpE's early bactericidal activity in patients with pulmonary TB, suggesting it could replace isoniazid in current treatment regimens or be added to future therapies [3][5]. - The trial was completed in April 2024 and involved a collaboration with TASK, GSK, and BioVersys [3]. Drug Mechanism and Collaboration - Alpibectir (AlpE) operates through a novel mechanism that enhances the efficacy of the existing antibiotic ethionamide, identified through a collaboration with GSK and academic institutions [2][5]. - The development of AlpE has been supported by various European Union grants and public-private partnerships, including the EU Innovative Medicines Initiative [4]. Industry Context - Tuberculosis remains a leading cause of death from infectious diseases globally, with increasing drug resistance complicating treatment efforts. In 2024, an estimated 10.7 million people developed TB, with approximately 1.23 million fatalities [9][10]. - The burden of TB is concentrated in 30 high-burden countries, with India, Indonesia, and the Philippines among the top contributors to global TB cases [11].

On February 13, Chief Market Strategist at Carson Group Ryan Detrick and CEO of MCC Global Enterprises Michelle Caruso-Cabrera joined CNBC to discuss rising geopolitical tensions, tariff shifts, and whether tech weakness is a buying opportunity. Detrick shifted the focus to market performance and noted that it is Friday the 13th ahead of the President’s Day long weekend.Despite the geopolitical tension, he highlighted that the S&P 500 and the Dow have both risen for nine consecutive months on a total return ...